Cellebrite DI Ltd. $CLBT Stake Boosted by Bank of New York Mellon Corp

Bank of New York Mellon Corp raised its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 11.6% in the second quarter, Holdings Channel.com reports. The institutional investor owned 1,287,954 shares of the company’s stock after buying an additional 133,651 shares during the period. Bank of New York Mellon Corp’s holdings in Cellebrite DI were worth $20,607,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Envestnet Asset Management Inc. purchased a new position in shares of Cellebrite DI in the first quarter worth approximately $512,000. Sigma Planning Corp acquired a new position in Cellebrite DI in the 1st quarter worth approximately $233,000. Jennison Associates LLC purchased a new position in Cellebrite DI during the 1st quarter worth approximately $645,000. Allianz Asset Management GmbH acquired a new stake in Cellebrite DI during the 1st quarter valued at $476,000. Finally, KLP Kapitalforvaltning AS lifted its holdings in shares of Cellebrite DI by 62.9% in the first quarter. KLP Kapitalforvaltning AS now owns 22,800 shares of the company’s stock valued at $443,000 after purchasing an additional 8,800 shares in the last quarter. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on CLBT. Needham & Company LLC lifted their price target on Cellebrite DI from $22.00 to $24.00 and gave the company a “buy” rating in a report on Thursday. Weiss Ratings lowered Cellebrite DI from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Thursday. Wall Street Zen cut Cellebrite DI from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Bank of America increased their price target on shares of Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, JPMorgan Chase & Co. raised their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a report on Thursday. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $24.00.

Cellebrite DI Price Performance

CLBT opened at $18.45 on Friday. The company has a market capitalization of $4.42 billion, a PE ratio of -24.28, a price-to-earnings-growth ratio of 3.16 and a beta of 1.28. Cellebrite DI Ltd. has a fifty-two week low of $13.10 and a fifty-two week high of $26.30. The business has a 50-day moving average of $17.81 and a 200-day moving average of $16.68.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Wednesday, November 12th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.05). The firm had revenue of $126.03 million during the quarter, compared to the consensus estimate of $122.98 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The company’s quarterly revenue was up 17.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.14 EPS. Cellebrite DI has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities research analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.